Coherus BioSciences (CHRS) Reports Q3 Loss of $1.79
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.33 --0%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.79), versus ($6.23) reported last year. Revenue for the quarter came in at $16.1 million, versus $500 thousand reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Navios Maritime Partners (NMM) Tops Q2 EPS by 34c
- Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
